Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Imugene Limited ( (AU:IMU) ).
Imugene Limited has announced a change in the director’s interest, with Kim Drapkin acquiring 2,000,000 Restricted Stock Units (RSUs) without consideration. This issuance of RSUs, approved by shareholders, reflects the company’s commitment to align the interests of its leadership with stakeholders, potentially impacting its strategic direction and growth.
More about Imugene Limited
Imugene Limited operates in the biotechnology industry, focusing on the development of novel therapies for cancer treatment. The company is engaged in researching and developing innovative immuno-oncology therapies to improve the efficacy of cancer treatments for patients globally.
YTD Price Performance: 50.0%
Average Trading Volume: 158,054
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $198.4M
Learn more about IMU stock on TipRanks’ Stock Analysis page.
